Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

575 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.
John NA, Solanky BS, De Angelis F, Parker RA, Weir CJ, Stutters J, Carrasco FP, Schneider T, Doshi A, Calvi A, Williams T, Plantone D, Monteverdi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J; MS‐SMART Investigators. John NA, et al. Among authors: doshi a. J Magn Reson Imaging. 2024 Jun;59(6):2192-2201. doi: 10.1002/jmri.29017. Epub 2023 Oct 3. J Magn Reson Imaging. 2024. PMID: 37787109 Clinical Trial.
Dimethyl fumarate may still have a role in progressive multiple sclerosis.
Plantone D, De Angelis F, Doshi A, Chataway J. Plantone D, et al. Among authors: doshi a. Ther Adv Neurol Disord. 2016 Jul;9(4):344-5. doi: 10.1177/1756285616640396. Epub 2016 Apr 6. Ther Adv Neurol Disord. 2016. PMID: 27366242 Free PMC article. No abstract available.
Multiple sclerosis, a treatable disease.
Doshi A, Chataway J. Doshi A, et al. Clin Med (Lond). 2016 Dec;16(Suppl 6):s53-s59. doi: 10.7861/clinmedicine.16-6-s53. Clin Med (Lond). 2016. PMID: 27956442 Free PMC article. Review.
Multiple sclerosis, a treatable disease .
Doshi A, Chataway J. Doshi A, et al. Clin Med (Lond). 2017 Dec;17(6):530-536. doi: 10.7861/clinmedicine.17-6-530. Clin Med (Lond). 2017. PMID: 29196354 Free PMC article. Review.
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network. Connick P, et al. Among authors: doshi a. BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944. BMJ Open. 2018. PMID: 30166303 Free PMC article. Clinical Trial.
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S; MS-SMART Investigators. Chataway J, et al. Among authors: doshi a. Lancet Neurol. 2020 Mar;19(3):214-225. doi: 10.1016/S1474-4422(19)30485-5. Epub 2020 Jan 22. Lancet Neurol. 2020. PMID: 31981516 Free PMC article. Clinical Trial.
MS-SMART study: systematic sampling bias concerns - Authors' reply.
Chataway J, De Angelis F, Connick P, Parker RA, Doshi A, John N, Barkhof F, Sharrack B, Weir CJ, Chandran S; MS-SMART Investigators. Chataway J, et al. Among authors: doshi a. Lancet Neurol. 2020 Jun;19(6):479-480. doi: 10.1016/S1474-4422(20)30149-6. Epub 2020 May 26. Lancet Neurol. 2020. PMID: 32470412 Free article. No abstract available.
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Solanky BS, John NA, DeAngelis F, Stutters J, Prados F, Schneider T, Parker RA, Weir CJ, Monteverdi A, Plantone D, Doshi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J; MS-SMART Investigators. Solanky BS, et al. Among authors: doshi a. AJNR Am J Neuroradiol. 2020 Dec;41(12):2209-2218. doi: 10.3174/ajnr.A6809. Epub 2020 Nov 5. AJNR Am J Neuroradiol. 2020. PMID: 33154071 Free PMC article. Clinical Trial.
575 results